A cohort study in Cambodia followed people after treatment for tuberculosis for two years. It reports substantial improvement in the first year, but persisting respiratory symptoms, depressive symptoms and stigma in some survivors well beyond the end of treatment.
The published summary is brief and does not give the proportions affected, so the size of the problem cannot be stated from it. Its point is consistent with growing evidence of post-tuberculosis lung disease in high-burden countries: completing treatment is not the end of care.
India carries the world's largest tuberculosis burden, so this is directly relevant. Survivors with breathlessness or cough after treatment may have airflow obstruction, bronchiectasis or fibrosis, and many are never reassessed.
- Ask tuberculosis survivors about breathlessness and cough at and after the end of treatment.
- Consider spirometry in those with persisting respiratory symptoms.
- Screen for depression, which may persist after cure.
- Recognise stigma as a barrier to returning for follow-up.
Why it matters
Programmes count treatment completion as success, while survivors may live with lasting lung damage and low mood.
Don't overread it
The available summary gives no figures; the scale of persisting impairment in this cohort is not reported here.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free